Cold atmospheric pressure air plasma jet is a medical device that generates reactive oxygen and nitrogen species (RONS). These species effectively kill bacteria and stimulate wound healing process. This advanced plasma jet will significantly improve chronic wound treatment process, which is commonly found in bedridden and type-2 diabetes patients. With long-term treatment required for these chronic wounds , this causes a large burden in the healthcare system. Our company aims to provide this cutting-edge device to local hospitals, homecare and patient’s family.
Atmospheric air pressure plasma jet is electrically driven by direct-current pulse-modulation signal in kHz frequency. This advanced technology efficiently controls the gas temperature to below 40 degree Celsius while producing reactive oxygen and nitrogen species. The controlled conditions are suitable for chronic wound healing. The developed air plasma jet consumes relatively low power and is completely free of ambient air. It costs less than a dollar per patient per month.
When this cost-effective plasma jet enhances the wound healing process, it not only reduces patients and their family’s pain but also improve the quality of their living. Cost and time taken for normal wound dressing will significantly drop. As per technological standards, the device is compliant with the class-2 electrical medical device standard, IEC 6001-1 and biocompatible. Based on current technology, it is more difficult and more time is required to develop a new drug to eliminate multi-drug resistance bacteria. Basically, most drugs are large compound molecules. However, plasmas mostly provide atomic and single molecular species, which are much more reactive. This consequently overcomes one of the main issues of the existing technology.
Our primary application area is local healthcare hub or secondary hospitals, which cover most outskirt areas. It has more potential due to the large number of long-term care patients transferred from tertiary hospitals. The household or family units will be our secondary application area in which we expect to provide the product after adoption in the primary application. The existing device is a bench top model, designed for use in healthcare centres and suitable for hospital-based patients. However, there is a comparable number of bedridden patients at home. We are targeting to develop a handheld version of this device for this market. This version would strongly depend on the development of the battery or power source. The market size which is conservatively calculated from sales of one unit per secondary hospital in Thailand equals to 300,000,000 THB. This does not include the market for home units yet.